Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

Infuse for TLIF initially received FDA breakthrough device designation in April 2024. A new indication could expand treatment ...

A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the ...

The annual output value of China's GI products increased from 639.8 billion yuan (about $89.5 billion) in 2020 to 969 billion ...